四川科伦药业股份有限公司 财务管理制度 第一章 总则 第一条 为适应市场经济发展的需要，规范四川科伦药业股份有限公司（以下 简称"公司"）会计确认、计量和报告行为，保证会计信息质量，使公司的会计 工作有章可循、有法可依，公允地处理会计事项，以提高公司经济效益，维护股 东权益，制定本制度。 第二条 本制度根据《中华人民共和国会计法》《企业财务通则》《会计基础 工作规范》《企业会计准则——基本准则》及后续颁布的具体准则、应用指南、 解释及其他相关规定等国家有关法律、法规、部门规章及规范性文件，结合公司 具体情况及公司对会计工作管理的要求制定。 第三条 本制度适用于公司及全资、控股子公司（以下简称"子公司"），各 子公司可根据本制度，结合自身实际情况制定实施细则。 第二章 会计核算体制 第四条 财会组织体系及机构设置和职责 1.公司负责人对本单位财务管理制度的建立健全和有效实施以及经济业务的真 实性、合法性负责；公司财务管理工作在董事会领导下由总经理组织实施，公司 财务负责人对董事会和总经理负责。 2.公司设立财务总监岗位，财务总监即公司财务负责人，负责和组织公司财务 管理工作和会计核算工作；财务总监必须按规定的任 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-087 四川科伦药业股份有限公司 关于预计公司与石四药集团 2026 年度日常关联交易情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、关联交易概述 （一）概述 四川科伦药业股份有限公司及其控制的公司（以下简称"公司"、"本公司" 或"公司及其下属企业"）与石四药集团有限公司及其子公司（以下简称"石四 药集团"）发生的关联交易是指公司与关联方石四药集团之间因采购、销售商品 和提供/接受服务等形成的日常关联交易。 根据《深圳证券交易所股票上市规则》第 6.3.3 条的规定，石四药集团为公 司关联法人。 公司 2026 年度与石四药集团之间的交易总额预计不超过 25,773 万元。公司 于 2025 年 12 月 23 日召开的第八届董事会第十次会议以 9 票赞成、0 票反对、0 票弃权审议通过了《关于预计公司与石四药集团 2026 年度日常关联交易情况的 议案》，不涉及应回避的董事。该议案不需要提交股东会审议，提交董事会前已 经公司独立董事专门会议审议通过。 | 关联交易类别 | 关联 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-088 四川科伦药业股份有限公司 关于预计公司 2026 年度部分日常关联交易情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、日常关联交易概述 （一）概述 本议案所涉公司日常关联交易是指四川科伦药业股份有限公司及子公司（以 下简称"公司"或"本公司"）与关联方华润科伦医药（四川）有限公司及其下 属子公司（以下简称"华润科伦"）发生的商品销售、材料采购、接受及提供劳 务，与关联方伊犁恒辉淀粉有限公司（以下简称"恒辉淀粉"）发生的委托加工 原材料和材料采购，与伊犁顺鸿生态农业科技开发有限公司（以下简称"伊犁顺 鸿"）发生的商品销售形成的关联交易。 华润科伦系公司董事、总经理刘思川先生担任董事的公司，根据《深圳证券 交易所股票上市规则》第 6.3.3 条的规定，华润科伦为公司关联法人。恒辉淀粉、 伊犁顺鸿系本公司董事、总经理刘思川先生控股的四川科伦兴川生物科技有限公 司（以下简称"科伦兴川"）控制的公司，根据《深圳证券交易所股票上市规则》 第 6.3.3 条的规定，恒辉淀粉、伊犁顺鸿为公 ...

四川科伦药业股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）第八届董 事会第十次会议通知于 2025 年 12 月 19 日以电话和电子邮件方式送达全体董事 和高级管理人员。第八届董事会第十次会议于 2025 年 12 月 23 日以通讯的方式 召开，会议应到董事 9 人，实到董事 9 人，公司高级管理人员列席了会议。会议 的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、行 政法规、部门规章、规范性文件和《公司章程》的规定，作出的决议合法有效。 证券代码：002422 证券简称：科伦药业 公告编号：2025-086 三、以 9 票同意、0 票反对、0 票弃权，审议通过了《关于修订<财务管理 制度>的议案》 为适应市场经济发展的需要，规范公司会计确认、计量和报告行为，保证会 计信息质量，使公司的会计工作有章可循、有法可依，公允地处理会计事项，以 提高公司经济效益，维护股东权益，公司根据《中华人民共和国会计法》《企业 财务通则》《会计基础工作 ...

精彩内容 近期，集采消息频传：江苏63个品种集采开标在即，国采1-8批接续来袭，浙江拟开展第六批集采，河南34个国采可替代、用量大、金额高的药品集采提 上日程，不乏顺铂注射剂等同为国家基药和医保甲类药品种，以及丙帕他莫注射剂等2024年在河南省公立医院终端销售额超8000万元的畅销药。国家重磅 会议释放新一轮国采信号，超140个品种满足7家及以上的企业竞争格局，齐鲁、远大、倍特等过评品种数惊人。 集采品种目录再优化，聚焦可替代、用量大、金额高 今年4月，河南省医保局发布《关于开展部分药品信息摸底工作的通知》（下文简称《通知》），拟对47个国采可替代药品进行摸底，并纳入参考监测清 单。 时隔约8个月（12月9日），《河南省牵头34种药品省际联盟采购规则要点（征求意见稿）》（下文简称《意见稿》）出炉，河南牵头拟对34个国采可替代 品种以及本省遴选的用量大、金额高药品开展新一轮带量集采（下文简称"河南省集采"）。 来源：河南省医保局 从集采品种上看，《意见稿》对比《通知》剔除了氨溴索口服液体剂、硝酸异山梨酯口服常释剂型、左西替利嗪口服液体剂、脂肪乳(C14-24)注射剂、普 拉洛芬滴眼剂、七氟烷吸入剂、卡铂注射剂、 ...

Investment Rating - The report maintains a focus on the innovative drug and medical device industry chain, indicating a high level of interest in this sector [1][6]. Core Insights - The innovative drug sector is experiencing high prosperity, with a recommendation to pay attention to pharmaceutical companies that are likely to see a revaluation of their value, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][25]. - The report highlights the Biopharma/Biotech sector, which is expected to see performance improvements as innovative pipelines are realized, with companies like Innovent Biologics, BeiGene, and others being of particular interest [6][25]. - Attention is also drawn to CXO and upstream companies benefiting from innovation, including WuXi AppTec and WuXi Biologics [6][25]. - The report emphasizes the potential recovery of leading medical device companies such as United Imaging Healthcare and Lepu Medical [6][25]. Summary by Sections A-Shares Performance - In the third week of December 2025, the A-share pharmaceutical sector performed similarly to the overall market, with the Shanghai Composite Index rising by 0.03% and the SW Pharma and Biotech index falling by 0.1%, ranking 19th among Shenwan primary industries [8][10]. - Sub-sectors that performed relatively well included pharmaceutical commerce (+4.9%), medical equipment (+1.2%), and medical services (+0.5%) [10][25]. - Notable individual stock performances included Anhui Huaren Health Pharmaceutical Co., Ltd. (+55.9%), Luyan Pharma (+36.8%), and ShuYu Civilian (+35.7%) [13][25]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Index down by 1.1% [19][25]. - In contrast, the U.S. pharmaceutical sector outperformed the market, with the S&P Healthcare Select Sector rising by 0.6% compared to the S&P 500's 0.1% increase [19][25].

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

分红方面，科伦药业A股上市后累计派现68.98亿元。近三年，累计派现35.87亿元。 机构持仓方面，截止2025年9月30日，科伦药业十大流通股东中，中欧医疗健康混合A（003095）位居 第三大流通股东，持股4006.24万股，相比上期减少253.71万股。香港中央结算有限公司位居第四大流通 股东，持股3472.80万股，相比上期减少525.83万股。广发多因子混合（002943）位居第五大流通股东， 持股2423.35万股，持股数量较上期不变。工银前沿医疗股票A（001717）位居第六大流通股东，持股 2000.00万股，相比上期减少700.88万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持股 1908.41万股，相比上期减少98.91万股。易方达沪深300医药ETF（512010）位居第十大流通股东，持股 1403.83万股，相比上期减少430.40万股。广发医疗保健股票A（004851）退出十大流通股东之列。 责任编辑：小浪快报 融券方面，科伦药业12月19日融券偿还900.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量20.44万股，融券余额647 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

Group 1 - The core viewpoint of the article highlights the impressive transformation of Kelun Pharmaceutical, showcasing its full-chain innovation capabilities in the ADC drug sector and synthetic biology, establishing a model for innovation-driven development in Chinese pharmaceutical companies [1][4][5]. Group 2 - In the ADC drug field, Kelun has become a representative enterprise in China, with its product, Lukanasatuzumab (Jiatailai®), being the first domestically developed ADC drug to receive full approval and global intellectual property rights [4]. - The company has initiated 15 global Phase III studies for Lukanasatuzumab in collaboration with Merck, targeting prevalent cancers such as lung and breast cancer, demonstrating its global innovation potential [4]. - Kelun has multiple ADC drug pipelines, with SKB518, SKB500, and SKB571 in Phase II clinical trials, and the NDA for another ADC drug, Botuzumab (HER2 ADC Shuitailai®), approved in October, showing significant efficacy advantages over traditional drugs [4]. Group 3 - In synthetic biology, Kelun has established a commercial system around "synthetic biology" through a strong fermentation technology platform and increasing R&D investment, successfully applying cutting-edge technology to high-value product development [5]. - The company is leveraging AI technology to enhance synthetic biology research and optimize production processes, leading to cost reduction and efficiency improvements [5]. - Kelun has successfully brought several products, including Red Methyl Alcohol, 5-Hydroxytryptophan, and others, into production and sales, becoming one of the first domestic companies to deliver products in the synthetic biology sector [5].